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Abstract Women from breast cancer families without a
demonstrable BRCA1/2 mutation were subjected to annual
mammography from age 30 years onwards. One-hundred
and ninety-eight patients were diagnosed prospectively
with invasive breast cancer and followed for a total of
1513 years. Overall 10-year survival was 88 %. Together
with our previous report that women in such kindreds had
about twice the population risk of breast cancer, the com-
bined conclusion was that the overall chances of develop-
ing breast cancer causing death within 10 years before
50 years of age was 1 % or less when subjected to annual
mammography and current treatment. These are empirical
prospective observations which may be used for genetic
counselling. The majority (160/194 = 84 %) of patients
had ER? and/or low grade tumours with 92 % 10-year
survival. One minor group of the patients had ER- tu-
mours, another small group had high grade tumours with
nodal spread, both groups were associated with worse
prognosis, but the two groups were not mutually
associated.
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Introduction
Family history has been used to identify women at in-
creased risk of developing breast cancer [1]. Women at
increased breast cancer risk have been subjected to annual
mammography for early diagnosis aiming for early treat-
ment with the hope of improving prognosis [2–5]. The two
collaborating centres issuing this report initiated clinical
activities more than 20 years ago as open prospective trials,
referring all women at appropriate risk to undergo annual
mammography. Follow up has been actively sought ef-
fectively making the study an open prospective observa-
tional trial. We have tested all breast cancer kindreds seen
throughout these years for BRCA1/2 mutations [6–10], and
we have reported risk for breast cancer in healthy women
in breast cancer kindreds without a demonstrable BRCA1/2
mutation [11]. Women with two or more close relatives
with breast cancer had 4 % risk for breast cancer before
50 years of age. We here report survival when breast
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Methods
The series include all cases subjected to annual mam-
mography having increased risk for breast cancer due to
family history from the outpatient cancer genetic clinics
in Manchester (UK) and Oslo (Norway). The Norwegian
series included 4115 patients and was censored in
September 2013. The UK series included 9500 patients
and was censored in October 2013. Women at increased
breast cancer risk from families without a demonstrable
BRCA1/2 mutation were subjected to annual mammog-
raphy from age 30–35 years onwards. The annual ex-
aminations were performed in dedicated breast cancer
diagnostic centres. Examination did not routinely include
ultrasound, or MRI, although clinical breast examination
was carried out in Manchester. However, USS and occa-
sionally MRI were performed with low threshold if indi-
cated by the results of the mammographic examination.
Follow-up for diagnosing cancer was from first to last
prospectively planned mammography; in Manchester,
women were also checked on the local cancer registry for
breast cancer within 2 years after last mammography. In
this way, none were lost to follow-up. How the Norwe-
gian and Manchester series were ascertained and ge-
netically tested to exclude causative BRCA1/2 mutations,
has previously been described in detail [11, 12]. In short,
(a) all available breast and ovarian cancer cases, (b) and/
or obligate carriers in the families and (c) all prospec-
tively diagnosed cases were examined by sequencing and
MLPA methods, additionally in Norway—if none such
were available—(d) healthy women at risk themselves
were tested. All families where one or more persons with
causative mutation(s) were found, were excluded from the
present study.
In the Norwegian series, women at high and moderate
breast cancer risk as described in the previous report [11]
as well as women with a male relative between the breast
cancer case and themselves were initially selected. In the
UK series, all women at high or moderate risk (lifetime risk
of 1 in 6 or higher [2, 4] based on family history were
selected. All cases with breast cancer prior to inclusion or
at first prospective mammography were excluded. All
breast cancer cases, irrespective of mode of detection, after
first prospectively planned mammography were assessed.
Survival after first diagnosed breast cancer was calculated,
any possible second cancer in any organ was not consid-
ered besides for cause of death as described below. Follow-
up after cancer included clinical follow-up and continued
annual mammography or more frequent according to
treatment regimen. In addition, all patients alive according
to our medical files when study was censored were checked
against population registry for being alive.
The following observations were used for this study: age
at diagnosis, age at last follow-up/age at death if dead,
tumour size, histopathological grade (grade) scored as low
(1), intermediate (2) or high (3), oestrogen receptor (ER)
positive (?) or negative (-), carcinoma in situ (CIS)/in-
vasive carcinoma without nodal spread at diagnosis/nodal
spread at diagnosis and the cancers were scored as ductal or
lobular. Mode of the breast cancer diagnosis was not in-
cluded as a variable in the present study. Only a few tu-
mours had been tested for HER2 as this was not routine
until recently, therefore, HER2 status was not included in
the analyses.
Associations between categorised variables were con-
sidered by Chi square tests. Differences in distributions for
continuous variables were assessed by two-sample t tests.
Survival was estimated by the Kaplan–Meier algorithm as
time from diagnosis to last follow-up/death. Each patient
was scored as alive or dead when censored. Causes of death
were identified from the medical files and cancer registry
(UK) and patients having died of causes other than breast
cancer and not having had spread from breast cancer when
dying, were censored as alive to derive a disease-specific
survival. Univariate and multivariate hazard rates (HR) for
death were calculated by using the Cox proportional hazard
method.
Ethics
All patients had consented to genetic testing according to
national legislation for health care, and all patients had
consented to the current research as approved by national
ethical committees.
Results
Two-hundred and forty-one patients were diagnosed to
have cancers, 172 (71 %) were screen detected and 69
(29 %) were interval cancers. Of the screen detected can-
cers, 42 (24 %) were palpable.
Forty-three cases (18 %) had CIS (39 ductal and 4
lobular) and were excluded from further analyses.
Out of 198 cases with infiltrating breast cancer, 194 had
been examined once or more after diagnosis and were in-
cluded in the survival analyses. Mean and median ages at
diagnoses were 49.5 and 49.0 years, respectively. They had
been observed for a total of 1513 person years, with a mean
of 7.6 years and median 7.1 years.
Fifty-four percent of the cases were aged less than
50 years at diagnosis. Eighty-seven percent of the cancers
were ductal, 75 % were node negative, 78 % were ER?
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and 63 % were grades 1 or 2. Median and mean tumour
size at diagnosis was 13 and 15.7 mm, respectively.
Nineteen (10 %) had died. See Table 1 for details.
Table 2 shows mean tumour sizes and ages at diagnosis,
and differences as judged by two-sample t tests. Lobular
cancers were larger and diagnosed at an earlier age than
ductal cancers. Grade 3 tumours were larger than grade 1
tumours (p = 0.000), cases with node positive had larger
tumours than node negative cases, while there was no
difference in size between ER- and ER? tumours. There
was an insignificant trend that those having died had larger
tumours at diagnosis than those still alive.
Survival in different groups is given in Table 3. 5- and
10-years survival in all cases were 93 and 88 %, respectively,
and there was no difference in survival between the UK and
the Norwegian series (Fig. 1). Survival in ductal and lobular
cases was similar. Survival was similar in patients aged less
than 50 versus more than 50 years at diagnosis (Fig. 2). No
case with a grade 1 tumour had died. Cases with ER? grade 2
tumours also had good prognosis. Eighty-two percent had
grade 1 or grade 2 or ER? tumours and as a combined group
had 92 % 10-years survival. ER-, and N? (Fig. 3) and Grade
3 (Fig. 4) were associated with a higher likelihood of death
(p = 0.000). ER- tumours were associated with increased
mortality even when node negative cases were considered
separately (Fig. 5), while tumour grade was not significantly
associated with death in node negative cases (Fig. 6).
Grade and nodal status were highly associated
(p = 0.000), but ER and nodal status at diagnosis were not
associated, p = 0.25 (Table 4).
By univariate Cox proportional hazard, ER, grade and
nodal status were associated with death, while age at
Table 1 Findings in 198
infiltrating breast cancer cases
by categorized variables
Scoring Subgroups Number of cases
(% of valid cases)
in subgroup
Type (n* = 193) Ductal 168 (87 %)
Lobular 25 (13 %)
Age groups (n* = 198) \50 years 106 (54 %)
C50 years 92 (46 %)
Nodal status at diagnosis (n* = 197) Node negative 147 (75 %)
Nodal spread 50 (25 %)
ER-status (n* = 185) Negative 40 (22 %)
Positive 145 (78 %)
Grade (n* = 192) Low 38 (20 %)
Intermediate 83 (43 %)
High 71 (37 %)
Censored (n* = 198) Alive 179 (90 %)
Dead 19 (10 %)
Centre (n* = 198) Norway 69 (35 %)
Manchester 129 (65 %)
n* number of cases with valid information in selected group
Table 2 Results of two-sample




p Mean age at
diagnosis (years)
p
Ductal 14.9 0.03 49.1 0.007
Lobular 23.5 53.2
Grade 1 9.6 0.000 49.5 0.72
Grade 3 18.4 49.9
Node pos 22.1 0.000 49.6 0.97
Node neg 13.8 49.5
ER negative 17.1 0.59 48.7 0.57
ER positive 15.8 49.5
Dead 22.0 0.12 48.7 0.67
Alive 15.4 49.6
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diagnosis and tumour size at diagnosis were not associated
with death (Table 5).
By multivariate Cox proportional hazard ER, grade and
nodal status were associated with increased mortality while
age and size were not (Table 6).
Discussion
Overall 10-year survival in initially healthy women from
BRCA1/2 negative familial breast cancer families, who had
prospectively detected cancers when subjected to annual
Table 3 Survival in different groups and results of Mantel tests for differences between groups







All All 194 93 % (88–96) 88 % (81–92)
Norway 69 94 % (85–98) 90 % (78–95) 0.85
Manchester 125 92 % (84–96) 88 % (79–93)
\50 years 103 95 % (87–98) 88 % (77–94) 0.80
50 ? years 91 91 % (82–95) 87 % (77–93)
Ductal 165 93 % (87–96) 89 % (81–93) 0.33
Lobular 24 91 % (66–98) 85 % (60–95)
ER neg 40 74 % (56–86) 67 % (52–83) 0.000
ER pos 142 98 % (93–99) 93 % (85-97)
Grade 1 38 100 % 100 % 0.000
Grade 2 81 96 % (87–99) 96 % (87–99)
Grade 3 69 85 % (72–92) 72 % (57–83)
N- 143 96 % (91–98) 94 % (88–97) 0.000
N? 50 83 % (67–91) 69 % (51–82)
Grade 1, Grade 2 or ER? 160 96 % (91–99) 92 % (85–96)
N- Grade 1 38 100 % 100 % 0.11
Grade 2 64 96 % (86–99) 96 % (86–99)
Grade 3 38 91 % (75–97) 87 % (69–95)
ER pos 107 100 % 99 % (91–100) 0.000
ER neg 26 79 % (57–91) 74 % (50–87)
Grade 3 and ER- 31 73 % (51–86) 63 % (40–79)
N ? and ER- 13 63 % (29–85) 53 % (20–77)
N ? and Grade 3 and ER- 11 55 % (18–81) 41 % (10–71)
Fig. 1 Survival by country Fig. 2 Survival by age at diagnosis
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mammography, was 88 %. These results add to our pre-
vious report that women in such kindreds had about twice
the population risk of breast cancer, and may be used for
genetic counselling. Considering the previous and the
current findings together, the risk of developing a breast
cancer before 50 years of age was about 2 %, which
multiplied by a 12 % risk of dying from that breast cancer
within 10 years, when subjected to annual Mx from
30 years of age, gives a combined risk of less than 1 % to
contract an early breast cancer causing death within
10 years. Or—vice versa—the probability to not have an
early breast cancer causing death within 10 years was
[99 %. These were our combined empirical observations
in patients from breast cancer kindreds without demon-
strable BRCA mutations subjected to annual
mammography from 30 years of age and with current
breast cancer treatment. These data could be used for ge-
netic counselling of women at moderate breast cancer risk.
With the increasing availability and reduced cost of
genetic testing, one may consider testing a healthy woman
with a family history of breast cancer directly and not—as
has been done so far—test affected relatives initially. If
doing so, the question of risk for breast cancer in BRCA1/2
carrying kindreds in women not having the family’s BRCA
mutation will become an issue to clarify [13], as will the
biology of such breast cancers. There is a possibility that
some families with highly penetrant BRCA1/2 mutations
may have additional (genetic) factors causing breast cancer
(independently or modifiers of BRCA1/2 penetrance).
Studies are ongoing to address this.
Fig. 3 Survival by nodal status at diagnosis p = 0.000
Fig. 4 Survival by tumour grade p = 0.000
Fig. 5 Selection node negative survival by ER receptor status
p = 0.000
Fig. 6 Selection node negative survival by tumour grade p = 0.11
Breast Cancer Res Treat (2015) 152:87–94 91
123
We have reported the outcome of our health service as
applied since the start of the activity. The scope of our
study was survival from breast cancer in those accepting
our offer of annual mammography from 30 years onwards
and current treatment once cancer was diagnosed. The
examinations were part of the health care system, and both
patient compliance and capacity problems in the diagnostic
outpatient clinics might have postponed some examina-
tions for some time. We did not focus on screen-detected
versus interval cancers (which anyway is difficult when
some patients because of the frequent examinations felt a
lump but did not inform us until the next scheduled
mammography). If considering details on time between
examination, screen-detected versus interval cancers, and
compared those with tumour characteristics such as grade,
ER, nodal status and size, the strata would be too many for
meaningful calculations in our limited series. The results
were that most patients in this highly selected series had
low grade and/or ER? tumours which was associated with
very good survival. Survival was so good that stratification
of this group with respect to survival is of little interest. In
contrast, two infrequent subgroups (ER- and high grade)
had worse outcome, and numbers did not allow meaningful
substratification of these two groups. These patients are
now being subjected to sequencing for many more genes
known to be associated with breast cancer in search of
biological causative factors.
Surprisingly, young age at diagnosis was not associated
with worse survival as has been previously published for
unscreened women [14, 15] (Figure 2). We were not able to
conduct a direct comparison with similar family history
positive women not undergoing intensive mammography
screening. However, it is of note that the 88 % 10-year sur-
vival for invasive breast cancer compares favourably to the
71.5 % 10-year survival for all women in the UK diagnosed
in 2000–2001 [16] approximating to the median age at di-
agnosis in our report. Survival in unscreened family history
positive women diagnosed with breast cancer in the UK
under 40 years of age between 2000 and 2008 was poor in a
recent study with only 70 % being alive without metastasis at
a mean of 7-year follow-up [16] and with 8-year overall
survival of only 67.3 % for all women [15]. Also, 10 year
survival was better in the group described here than in in-
herited breast cancer caused by BRCA1 mutations [17].
The associations between the findings lead us
to the following speculations
A small proportion of the cases had grade 3 and/or ER-
and/or were node positive and carried a worse prognosis,
but ER- and node positive were not associated with each
Table 4 Nodal status at diagnosis versus tumour receptor status and
grade
Node negative Node positive p
ER- 26 13 0.25
ER? 110 35
Grade 1 38 0 0.000
Grade 2 66 17
Grade 3 40 30
Table 5 Results univariate Cox proportional hazard for death
Number of cases Number of deaths HR (95 % CI) p value log-rank p value
Age
25–49 94 7 1 0.425
50? 81 10 1.48 (0.56–3.89) 0.428
Size
0.1–1.0 cm 63 4 1 0.147
1.1–2.0 cm 72 6 1.28 (0.36–4.55) 0.700
2.1–7.0 cm 40 7 2.89 (0.85–9.86) 0.091
ER
Negative (1) 38 10 1 0.00016
Positive (3) 137 7 0.19 (0.07–0.50) 0.001
Grade
Low* or intermediate 108 3 1 0.00006
High 67 14 8.38 (2.41–29.18) 0.001
Nodal status
Negative 130 6 1 0.00004
Positive 45 11 6.28 (2.32–17.01) 0.0003
* No death in cases with low grade
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other. It is interesting that the effect on mortality on having
a tumour an ER- tumour and being node positive, was
additive (Table 3). Numbers included were, however,
limited, and we look forward to see results from other
centres on this specific issue.
Conclusions
In women at increased familial breast cancer risk without a
demonstrable BRCA1/2 mutation, the overall chances of
developing breast cancer causing death within 10 years
before 50 years of age was less than 1 % when subjected to
annual mammography and current treatment. The majority
of patients had ER? and/or grade 1 or 2 tumours, and
survived. A minor fraction of the patient had ER- tumours
and/or nodal spread at diagnosis, both of which were as-
sociated with worse prognosis but ER? and nodal spread at
diagnosis were not associated. The results to us indicated
that annual mammography from 30 years of age should be
continued while the search for more genes that cause in-
herited breast cancer continues [18]. Hopefully, one may
arrive at understanding why some patients have worse
prognosis and develop more effective personalised pre-
ventive and/or treatment modalities.
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